Sign up
Pharma Capital
Market: AIM
52-week High/Low: 15.70p / 4.90p
Sector: Health Care, Equipment & Services
Market Cap: 7.95M

Concepta is a UK- based Women’s Healthcare company which has been founded to help women with unexplained infertility to conceive.

Typically, medical intervention for infertility does not start until 12 months of a woman unsuccessfully trying to conceive, with IVF only being offered after two years of trying to conceive in most countries.

Research indicates that couples start to take...


Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Concepta

Concepta Snapshot

Growth Strategy

  • Continue the manufacture, marketing and R&D of MyLotus product, the proprietary fertility and pregnancy monitoring device
  • Market and distribute into China in 2016 – market demand has been identified
  • Roll product out through Europe – targeting UK and German markets first
  • Increase market penetration in China and Europe and look to expand into new territories
  • Utilise IP to develop other home-health monitoring products for wider family unit to improve individual health parameters incl. chronic stress, inflammation et al.






Our flagship product MyLotus has a unique offering, allowing women to see YES / NO results as well as their actual and personal level of factors that can have a direct influence on fertility – MyLotus is the only home-test on the market that currently offers this.

MyLotus has the ability to quantify personal hormone levels enabling the identification of the fertile period for a large number of women, especially for the significant amount of women whose hCG and LH levels vary from mean levels.

MyLotus addresses the issue of timing of intercourse in relation to your fertility hormones.

It can detect the actual concentration of the hormones in a woman’s urine sample allowing detailed analysis into issues with ovulation and fertility that aren’t available with other home tests on the market. This kind of data highlights the key dates in the cycle when the woman is the most fertile, improving chances of conception as well as potential areas where the woman can seek specialised medical advice.



You can only conceive for two fertile days in any given cycle, so being able to accurately predict when these days will fall is crucial. The easy-to-use MyLotus ovulation test enables this by measuring the level of lutenising hormone (LH) in your urine. A surge in LH level indicates that ovulation is likely to happen in the next 24-48 hours.

Many women have a low base level of LH, so being able to test the concentration of the LH hormone is a huge benefit. MyLotus is the first commercial test to do this and makes home ovulation testing relevant for all women.

The tests are wrapped in protective aluminium foil and a plastic cup and pipette are provided for collecting and testing your urine. Nowadays most women are used to a midstream urine test format. MyLotus takes away the common concern of whether too much or too little urine was sampled. We provide a pipette with every test and you will apply the same volume of urine each time.

MyLotus is suitable for all women.



This test will measure the level of human chorionic gonadotrophin (hCG) in your urine. This is the hormone that is produced when you are pregnant.

Like other pregnancy tests the product can pick up a pregnancy early, but reliability improves the closer you get to the missed period. The app will ask you to begin testing yourself in the 2 days prior to your expected period and the test is 99% reliable when conducted on the day of the missed period.



A free downloadable app allows you to track your fertility on your mobile. The app will learn about your individual cycle and will send you a prompt when a test should be done.

The app can be used as a stand alone fertility tracker or combined with the MyLotus test to add real personalised data to the tracker. This is particularly useful to women who are struggling to conceive with standard home testing kits or cycle-based fertility trackers.

When used in a combined way the app will store details from your past tests and previous cycles and could provide valuable information for your doctor which could, for example, allow them to better identify the day of conception and to calculate your due date.

Issued share capital will consist of 109,625,247 ordinary shares of 2.5p each

Percentage of AIM securities not in public hands is 2.88 per cent.

This information was last updated on 8 March 2017

Shareholdings holding over 3%

Shareholder Ordinary Shares Issued Share Capital (%)
Mercia Technologies PLC 19,999,999 18.32
Finance Yorkshire Seedcorn Fund 12,699,997 11.63
Angel CoFund 11,668,267 10.69

Directors Shareholding

Shareholder Ordinary Shares Issued Share Capital (%)
A Reynolds 1,155,555 1.06
E Henau 293,333 0.267
B Spurrier 246,057 0.23
N Herbert 1,530,729 1.40



The Exchange
Colworth Park
MK44 1LQ

Telephone: 01234 866601
General Email: [email protected]



Yellow Jersey PR Limited
1st Floor
30 Stamford Street,

Yellow Jersey PR Ltd
Telephone: +44 (0)203 735 8825.

Nominated Adviser

SPARK Advisory Partners Limited
5 St John’s Lane
London EC1M 4BH


Beaufort Securities Limited
Beaufort Securities Ltd
131 Finsbury Pavement
London EC2A 1NT

Solicitors to the Company

BPE Solicitors LLP
St James House
St James Square
Cheltenham GL50 3PR

Solicitors to the Nominated Adviser

Addleshaw Goddard LLP
Milton Gate
Chiswell Street
London EC1Y 4AG

Reporting Accountant & Auditor

Jeffreys Henry LLP
5 – 7 Cranwood Street
London EC1V 9EE


Neville Registrars Limited
Neville House
18 Laurel Lane
Halesowen B63 3DA

View full CPT profile View Profile
View All

Market Reports Including CPT


Executive video interviews


© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.